Actinium Pharma

Q2 FY2026 EarningsQ2 FY26 reported a significant beat on the bottom line primarily due to the one-time recognition of $35.0M in deferred license revenue, resulting in GAAP EPS of $0.89 vs. the -$0.20 expected. While commercial revenue remained at zero, the GAAP Net Income of $27.9B substantially exceeded the consensus of -$6.2M. Management expects to report data for ATNM-400 and Actimab-A in 4Q 2026, while the cash runway is confirmed for more than 12 months following this report.